GILD

Gilead (GILD) Moves 3.3% Higher: Will This Strength Last?

Gilead Sciences (GILD) Dips More Than Broader Market: What You Should Know

Gilead's Breast Cancer Drug Trodelvy Wins FDA Nod for Expanded Use

U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer

Gilead Sciences: The Market Is Underestimating Its Growth Runway

European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors